Country for PR: United Kingdom
Contributor: PR Newswire Europe
Monday, November 21 2022 - 22:19
APR Applied Pharma Research (a Subsidiary of Relief Therapeutics) is a Finalist in the 2022 Rare Disease International Film Festival
GENEVA, Nov. 21, 2022 /PRNewswire-AsiaNet/ --

Swiss, commercial-stage biopharmaceutical company identifying, developing and 
commercializing novel, patent protected products in selected specialty, rare 
and ultra-rare disease areas on a global basis, today announced that its wholly 
owned subsidiary APR Applied Pharma Research <> SA ("APR") 
has been nominated as a finalist in the 2022 Rare Disease International Film 
Festival UnoSguardoRaro.

APR supports and contributes to the first and only European film festival 
showcasing films from around the world that address the challenges of life with 
a rare disease. APR's short movie, Forward – Live your best life 
<>, was nominated as a finalist 
among more than 200 participants by a jury of international experts comprised 
of patient associations, health care professionals and film makers. During the 
awards ceremony, the jury awarded APR's movie 2 prizes: Special Mention for 
Best Campaign and Best Direction.

"With our campaign Live your best life!, we highlight the emotional journey 
lived by PKU families, their difficulties in juggling with a strict diet and 
protein substitutes, and their eagerness to pursue their full potential in 
life," said Paolo Galfetti, Chief Executive Officer of APR, whose real-life 
story of becoming a father of a child with PKU inspired the movie. Paolo 
Galfetti commented on APR's work for his first child, Riccardo, born with the 
condition: "Knowing these products may be helpful for patients and families, 
who live with this rare disease, as for health care professionals, is our 
biggest reward. I'm proud of working with passionate people and of the results 
we achieved together. Being so involved both personally and professionally 
makes me even more proud of my son and the determined and energetic young man 
he became."

APR's approach was shaped by its ambition of creating a product that can 
respond to the needs of PKU patients and resulted in the creation of the PKU 
GOLIKE® line, a Food for Special Medical Purposes. APR's experience in 
identifying and applying pharmaceutical technologies to improve the efficacy 
and tolerability of molecules for common pathologies served as basis for 
improving the absorption of amino acid and allowing better metabolic management.

As part of its participation in the festival, APR attended events in Berlin (Il 
Kino), Rome (la Casa del Cinema) and Milan (Niguarda hospital). The festival 
earned the support of many rare disease associations such as:

- Eurordis <> - Rare Disease Europe
- ACHSE Allianz Chronischer Seltener Erkrankungen 
- Uniamo <> - Federazione Italiana Malattie Rare 


PKU GOLIKE® is a phenylalanine-free food intended for the dietary management of 
phenylketonuria ("PKU"). The product is comprised of a mixture of amino acids 
in the form of granules and is available in convenient packets and medical food 
bars. Engineered with the Relief's patented Physiomimicâ„¢ Technology platform, 
PKU GOLIKE® is the first prolonged-release amino acid product, characterized by 
a special coating that ensures physiological absorption of the amino acids 
mirroring that of natural proteins. In addition, the special coating masks the 
unpleasant taste, odor, and aftertaste of the amino acids. PKU GOLIKE® has been 
commercially available in the E.U. since 2019 and was launched in the U.S. in 
October 2022.

About Relief

Relief is a Swiss, commercial-stage, biopharmaceutical company focused on 
identification, development and commercialization of novel, patent protected 
products intended for the treatment of rare and ultra-rare diseases including 
metabolic disorders, pulmonary diseases, and connective tissue disorders. 
Relief's diversified pipeline consists of assets that have the potential to 
effectively address significant unmet medical needs, including PKU GOLIKE®, 
engineered with the proprietary physiomimic technology, which is the first 
prolonged-release amino acid product commercialized for the dietary management 
of phenylketonuria ("PKU"). Relief has a collaboration and license agreement 
with Acer Therapeutics for the worldwide development and commercialization of 
ACER-001 (sodium phenylbutyrate) for the treatment of various inborn errors of 
metabolism, including Urea Cycle Disorders ("UCDs") and Maple Syrup Urine 
Disease ("MSUD"). Relief also continues to develop aviptadil for several rare 
pulmonary indications. Further, Relief is in clinical development for 
APR-TD011, a differentiated acid oxidizing solution of hypochlorous acid 
intended for the treatment of epidermolysis bullosa ("EB"), a group of rare, 
genetic, life-threatening connective tissue disorders; APR-TD011 has been 
granted Orphan Drug Designation by the U.S. Food & Drug Administration. Relief 
is commercializing several legacy products via licensing and distribution 

RELIEF THERAPEUTICS Holding SA is listed on the SIX Swiss Exchange under the 
symbol RLF and quoted in the U.S. on OTCQB under the symbols RLFTF and RLFTD.

For more information, please visit Follow Relief on 

Jack Weinstein
Chief Financial Officer and Treasurer

LifeSci Advisors
Irina Koffler


This communication expressly or implicitly contains certain forward-looking 
statements concerning RELIEF THERAPEUTICS Holding SA. Such statements involve 
certain known and unknown risks, uncertainties and other factors, including 
those risks discussed in RELIEF THERAPEUTICS Holding SA's filings with the SIX 
and the Securities and Exchange Commission, which could cause the actual 
results, financial condition, performance or achievements of RELIEF 
THERAPEUTICS Holding SA to be materially different from any future results, 
performance or achievements expressed or implied by such forward-looking 
statements. RELIEF THERAPEUTICS Holding SA is providing this communication as 
of this date and does not undertake to update any forward-looking statements 
contained herein as a result of new information, future events or otherwise.

Photo -

Source:  Applied Pharma Research